68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT

Bone

Volumn 64, Issue , 2014, Pages 222-227

  Breer, Stefan ^a   Brunkhorst, Thomas ^b   Beil, F Timo ^a   Peldschus, Kersten ^a   Heiland, Max ^a   Klutmann, Susanne ^a   Barvencik, Florian ^a   Zustin, Jozef ^a   Gratz, Klaus Friedrich ^b   Amling, Michael ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

FGF23; Hypophosphatemia; Octreotide scintigraphy; Oncogenic osteomalacia; Tumor induced osteomalacia

Indexed keywords

CALCITRIOL; DOTA TATE GALLIUM GA 68; PENTETREOTIDE IN 111; PHOSPHATE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; GALLIUM;

ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MINERALIZATION; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENIC OSTEOMALACIA; ORTHOPEDIC SURGERY; PHOSPHATE BLOOD LEVEL; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; VITAMIN BLOOD LEVEL; COHORT ANALYSIS; COMPLICATION; DIAGNOSTIC USE; MULTIMODAL IMAGING; NEOPLASM; OSTEOMALACIA; RADIOGRAPHY; SCINTISCANNING;

ADULT; COHORT STUDIES; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASMS; OSTEOMALACIA; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84899812234     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.016     Document Type: Article

References (37)

1. Seijas R., Ares O., Sierra J., Perez-Dominguez M. Oncogenic osteomalacia: two case reports with surprisingly different outcomes. Arch Orthop Trauma Surg 2009, 129(4):533-539.
2. Woo V.L., Landesberg R., Imel E.A., et al. Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 108(6):925-932.
3. Ladha S.S., Whitaker M.D., Bosch E.P. Oncogenic osteomalacia: muscular weakness and multiple fractures. Neurology 2006, 67(2):364-365.
4. Econs M.J., Drezner M.K. Tumor-induced osteomalacia - unveiling a new hormone. N Engl J Med 1994, 330(23):1679-1681.
5. Farrow E.G., White K.E. Tumor-induced osteomalacia. Expert Rev Endocrinol Metab 2009, 4(5):435-442.
6. Ryan E.A., Reiss E. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med 1984, 77(3):501-512.
7. de Beur SM Jan, Streeten E.A., Civelek A.C., et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 2002, 359(9308):761-763.
8. Berndt T.J., Schiavi S., Kumar R. "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005, 289(6):F1170-F1182.
9. Yamazaki Y., Okazaki R., Shibata M., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002, 87(11):4957-4960.
10. Folpe A.L., Fanburg-Smith J.C., Billings S.D., et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004, 28(1):1-30.
11. Jiang Y., Xia W.B., Xing X.P., et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 2012, 27(9):1967-1975.
12. Reis-Filho J.S., Paiva M.E., Lopes J.M. August 2003: 47-year-old female with a 7-year history of osteomalacia and hypophosphatemia. Brain Pathol 2004, 14(1):111-115.
13. Chong W.H., Yavuz S., Patel S.M., Chen C.C., Collins M.T. The importance of whole body imaging in tumor-induced osteomalacia. J Clin Endocrinol Metab 2011, 96(12):3599-3600.
14. Chong W.H., Andreopoulou P., Chen C.C., et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res 2013, 28(6):1386-1398.
15. Houang M., Clarkson A., Sioson L., et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol 2013, 44(12):2711-2718.
16. Duet M., Kerkeni S., Sfar R., Bazille C., Liote F., Orcel P. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med 2008, 33(11):752-756.
17. Nguyen B.D., Wang E.A. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med 1999, 24(2):130-131.
18. Casari S., Rossi V., Varenna M., et al. A case of oncogenic osteomalacia detected by 111In-pentetreotide total body scan. Clin Exp Rheumatol 2003, 21(4):493-496.
19. Elston M.S., Stewart I.J., Clifton-Bligh R., Conaglen J.V. A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery. Bone 2007, 40(1):236-241.
20. Antunes P., Ginj M., Zhang H., et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging 2007, 34(7):982-993.
21. Clifton-Bligh R.J., Hofman M.S., Duncan E., et al. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab 2013, 98(2):687-694.
22. Hesse E., Moessinger E., Rosenthal H., et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res 2007, 22(1):158-162.
23. von Falck C., Rodt T., Rosenthal H., et al. (68)Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. Eur J Nucl Med Mol Imaging 2008, 35(5):1034.
24. Haeusler G., Freilinger M., Dominkus M., et al. Tumor-induced hypophosphatemic rickets in an adolescent boy - clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. J Clin Endocrinol Metab 2010, 95(10):4511-4517.
25. Naswa N., Sharma P., Kumar R., Malhotra A., Bal C. Successful localization of residual culprit tumor in a case of tumor-induced osteomalacia using 68Ga-DOTANOC PET/CT. Clin Nucl Med 2013, 38(8):639-640.
26. DVO Guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie 2011, 20:55-74.
27. Meyer G.J., Macke H., Schuhmacher J., Knapp W.H., Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004, 31(8):1097-1104.
28. Bordier P.J., Chot S.T. Quantitative histology of metabolic bone disease. Clin Endocrinol Metab 1972, 1(1):197-215.
29. Priemel M., von Domarus C., Klatte T.O., et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010, 25(2):305-312.
30. Jing H., Li F., Zhuang H., et al. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan. Eur J Radiol 2013, 11:2028-2034.
31. Wild D., Schmitt J.S., Ginj M., et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003, 30(10):1338-1347.
32. Rhee Y., Lee J.D., Shin K.H., Lee H.C., Huh K.B., Lim S.K. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf) 2001, 54(4):551-554.
33. Garcia C.A., Spencer R.P. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med 2002, 27(8):582-583.
34. Woff E., Garcia C., Tant L., et al. Imaging of tumour-induced osteomalacia using a gallium-68 labelled somatostatin analogue, BMJ Case Rep 2010, 10.1136/bcr.02.2010.2750.
35. Chong W.H., Molinolo A.A., Chen C.C., Collins M.T. Tumor-induced osteomalacia. Endocr Relat Cancer 2011, 18(3):R53-R77.
36. Hofman M.S., Kong G., Neels O.C., Eu P., Hong E., Hicks R.J. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 2012, 56(1):40-47.
37. Poeppel T.D., Binse I., Petersenn S., et al. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Recent Results Cancer Res 2013, 194:353-371.